DOCSLIB.ORG

Toxtalk Virginia Division Offorensic Sciences 1 North 14 Th St

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Toxtalk Virginia Division Offorensic Sciences 1 North 14 Th St Society of Forensic Toxicologists, Inc. P. O. Box 5543, Mesa, AZ 85211-5543 PhonelFax 602-839-9106 PRESIDENT JOHpb J. Saady, Pb.D. DABFT ToxTalk Virginia Division ofForensic Sciences 1 North 14 th St. Richmond. VA 232t9 IVOLUME 22, No.2 JUNE 19981 Tel 804-786-9151 Fax: 804-371-8328 EDITOR: Joseph R. Monforte, PhD, DABIT Email : [email protected] EDITORIAL BOARD: H. Chip Walls, B.S., Jim Wigmore, B.Sc., Daniel lsenschmid, Ph.D., DABIT. Vincent Papa, Ph.D. PUBLISHER: Patricia Mohn-Monforte VICE PRESIDF:NT Marilyn A. Huestis, Ph.D. LabofChem & Drug Merabolism IN THIS ISSUE ____________~_ Addiction Research Center NIDA. NIH 5500 Nathan Shock Dr. Baltimore, MD 21224 REGULAR FEATURES: Journal Club ~ Professional Calendar ~ Career Opportunities ~ Tel : 410-550-2711 From the Editor's Desk ~ Elmer Gordon ~ Drugs in The News ~ President's Message Fax: 410-550-2468 Email : Mlluestis(~ irp . nida . nih.gov TECHNICAL NOTES: Blutalkoholkonzentration ~ CASE NOTES: Comparison of Post­ mortem Heart and Peripheral Blood Ethanol Concentrations (IsenschmidlHepler). Vitreous Humor SECRETARY 6-Acetylmorphine (SaadylEnglandlValentour), and Strikingly High Concentrations of THCA in Urine: Misapplication of "Medicinal Marijuana" Through Improper Self-Diagnosis and Dosing? (Dunn) Mirbael L Smitb, Ph.D., DABFT ~ ed Forces Medical Examiner, AFIP ·ashington. DC 20306-{)OOO OF SPECIAL INTEREST: Interim SOFT Board Meeting ~ SOFTffIAFT '98 • el : 301-319-0100 Fax: 301-319-0628 INSERTS"': '98 SOFTffIAFT Meeting Materials Email : [email protected] TREASlJRER F~OH THE. £1)"O~'S DE.SK , , .. Joseph R. Monforte, Ph.D., DABFT J. Ro~rt Zeltl, U.s., M.P.A. Forensic Alcohol Consulrants. Inc. On page 9 of the previous issue of ToxTalk ( Volume 22, March 1998) there 1500 E. Mineral Place Linlelon. CO 80122-2911 appeared a summary of an article entitled "Marijuana and Actual Driving Performance," Tel 303-795-1654 submitted by Art McBay. The ToxTalk article incorrectly stated that driving tests were Fax : 303-795-1654 conducted in city traffic and on highways at speeds up to 26 miles per hour. It should have Email : JRZETTL(lilEC ENTRAL.COM stated that the driving tests were conducted at speeds up to 62 miles per hour. Please note the correction. ~ ADDITIONAL DIRECTORS Brure Gold~rger. Ph.D. VISIT THE SOFT WEBSITE: www.soft-tox.org Laurel J. Farrell, B.A. Daniellsensrhmid. Ph.D., DABFT Amanda Jenkins, Ph.D. Thomas F. Simon irk., B.S. ToxTalk is mailed quarterly (bulk mail) to members of the Society ofForensic Toxico logisfs. ex offido: Virkie W. Walls, M.S. Inc. It is each member's responsibility to report changes of address to the SOFT mailing address Joseph R. Monforte. Ph.D., DABFT (Mesa, AZ - above). Non-members may now receive ToxTalk for $15 per calendar year. Make (ToxTalk Editor) your check payable to SOFT, and mail it to the ToxTalk Editor. All members and others are encouraged to contribute to ToxTalk. Please mail your 1998 ANN{ IAL MEETING HOSTS contribution to : Joseph R. Monforte, Ph.D., DABFT, ToxTillk Editor N.G.S. Rao, Ph.D. I Ronald Barker, Ph.D. I .--" Vina Spiehler, Ph.D. 42408 N. Sombrero Rd, Cave Creek, AZ 85331-2821 0). Box 40711 Telephone: 602-595-MOHN (6646) Fax: 602-595-MONF (6663) - nfter 11 n.m. E.s.T. plense ."\Ibuquerque. NM 87196-071. I E-mail: [email protected] Tel: 505-841-2562 Fax: 505-841-2543 Email: [email protected] DEADLINES: Feb. 1, May 1, Aug. 1, and Nov.!. NEXT DEADLINE: August J, J998 SOFf is a supporting organization of the American Board of Forensic Toxicology PRESIDENT'S MESSAGE by Joseph Saady, Ph.D., DABFT THE ROOM CRUNCH We are running out of rooms for the SOFT Annual Meeting in Albuquerque. The Hilton is sold out, and the Fairfield is 50% sold out. The local committee in Albuquerque has obtained the maximum number of rooms from the hotels during this busy week. Reserve your room now, if you wish to attend! II EMPLOYMENT IN TOXICOLOGY - THIS MAY BE AS GOOD AS IT GETS If you expect that I have performed a thorough analysis of this subject, then read no further! I have not! But I do have colleagues throughout this country who have discussed their situations and tribulations related to this issue with me. As one who has changed employment within the past two years, I wish to reflect on this issue. Corporate downsizing, realignment, re-engineering, restructuring, consolidation, merger, etc. All of these synonyms mean one thing . Employees lose their jobs and thus their lives are disrupted. The remaining employees work longer hours and harder to "take up the slack." The remaining employed are acutely aware of the very real possibility of losing tlliill job and are, therefore, under greater mental stress to perform better and for longer hours. Work pressures are consuming more of our lives. Let's face the reality. As professionals, an attack on our work, our job, our livelihood goes to the very core of who we are . The workplace has changed! It has not been that many years ago when employers had a sense of responsibility and protection for the employee. Employees on the other hand had a sense of loyalty and dedication toward the employer. These ideas are more of the exception than the rule now. Exceptional work is frequently rewarded with additional burdens, for little or no additional monetary compensation. We are reading in the news that there are currently more people employed than ever before. But for toxicologists, it appears that the salaries are weak, and that there are more lower paying jobs. Actually many other professions and industr~ are experiencing simi'lar effects - with the exception of computer related jobs. What can toxicologists do to protect themselves? Learn! And learn constantly over your lifetime. Tackle tough prob:ems, and find solutions. Create a situation where the employer needs you more than you need them . If you have experience and have a demonstrated ability to solve problems, you are a valuable asset to any company. Your reputation , the manner in which you conduct yourself, your resume' , your skills and problem solving ability will stay with you . As companies outsource labor, many of our toxicologists have taken advantage of this opportunity in consulting services. Still others are finding ways to creatively use their toxicology background in forensically related fields. The Visioning Workgroup 1998 is now investigating (to the extent possible) the future of forensic toxicology. What are your ideas? Contact Dr. Carl Selavka at [email protected] or by fax at (518) 457-9384. And try to enjoy your job. This may be as good as it gets! ~ PRESIDENT SAADY ENCOURAGES YOUR INPUTI You may. .. E-mail , fax, or write to Joseph J. Saady, Ph.D., DABFT Virginia Division of Forensic Sciences, 1 North 14th Street, Richmond, VA 23219 e-mail at [email protected] fax to 804-371-8328 REMINDER TO SOFT BOARD MEMBERS AND COMMITTEE CHAIRS The SOFT Board Meeting will be held Tuesday, October 6th, at 6: 30 p.m. Report forms and more specific information will be distributed. Please make every effort to submit your report by the stated date. For further information, contact President Saady. ~ ToxTalk I 'oIl/me 22. No. 2 .June 1998 (Page 2) Copyright 1998 SOFT/TIAFT '98: ACT NOW! This may be your last opportunity to make hotel reservations for the SOFTITIAFT meeting. Space is very limited ---- j will be reserved on a "first come" basis only. To qualify for conference rates specify "SOFT" when making your I c:servations. Rates are not guaranteed after September 3rd . A third hotel has been added to try to accommodate attendees. Local phone numbers are listed below, the 800 national contacts may not recognize your SOFT discount. Albuquerque Hilton (Congress Hotel) 505-884-2500: $105 single/double; $115 triple; $125 quad Fairfield Inn by Marriott (same compound as Hilton) 505-889-4000: $89 single/double; $99 triple; $109 quad Holiday Inn Mountain View (across the parking lot from the Hilton): 505-884-2511 $99.95 single/double; $109.95 trip/quad Here are some important deadlines to remember: July 1st Abstracts must be submitted July 1st Free t-shirt with registration Aug . 1st Early registration. $50 late fee applies after this date Sept. 7th Last day mail registrations will be accepted Sept. 3rd Hotel reservation rate. guaranteed (but NOT room space) This year, you have two registration options. The basic difference between the Mesa and Sandia registrations is that the Mesa does not include the following: Wednesday and Friday luncheons, Farewell Banquet, Workshop #6, and the published Congress Proceedings. Additional information can be obtained by writing to: SOFT-TIAFT 1998, POBox 40711, Albuquerque, NM 7196-0771 or contact: N.G. Rao (SOFT) Phone: 505-841-2562 e-mail: [email protected] .us (THIS IS NEW) Ron Backer (SOFT) 915-561-8851 [email protected] Vina Spiehler (TIAFT) 714-642-0574 [email protected] Report of Interim Meeting of the SOFT Board of Directors Submitted by Michael L. Smith, Ph.D., DABFT, SOFT Secretary President Joseph Saady presided over the meeting held February 11 , 1998, in San Francisco, CA, during the annual meeting of the American Academy of Forensic Sciences. Committee reports were given and are highlighted. Kurt Dubowski 's Bylaws report indicated that there were no new bylaws since the last meeting and that a complete set of bylaws will be available soon in hard copy and electronic format. Marilyn A. Huestis, last year's secretary, announced that SOFT added 78 new members in 1997 bringing total membership to 562; 25 charter, 420 full, 88 associate, 19 retired and 10 student members.
Load more

Recommended publications
  • Innovation in Pain Management
    INNOVATION IN PAIN MANAGEMENT The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 12 December 2002 Edited by L A Reynolds and E M Tansey Volume 21 2004 ©The Trustee of the Wellcome Trust, London, 2004 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2004 The Wellcome Trust Centre for the History of Medicine at University College London is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 0 85484 097 7 Histmed logo images courtesy Wellcome Library, London. Design and production: Julie Wood at Shift Key Design 020 7241 3704 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Reynolds L A, Tansey E M. (eds) (2004) Innovation in Pain Management. Wellcome Witnesses to Twentieth Century Medicine, vol. 21. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Witness Seminars: Meetings and publications;Acknowledgements vii E M Tansey and L A Reynolds Introduction Christina Faull xix Transcript Edited by L A Reynolds and E M Tansey 1 Appendix 1 73 Extract from an annotated Physiological Society interview with Patrick Wall (1925–2001) by Martin Rosenberg and Steve McMahon (5 February 1999) Appendix 2 83 Morphine: Optimal potential for benefit with a minimum risk of adverse events and burden by Jan Stjernswärd (12 April 2004) References 85 Biographical notes 103 Index 115 Key to cover photographs ILLUSTRATIONS AND CREDITS Figure 1 Dr Cicely Saunders and two patients at St Joseph’s on their golden wedding anniversary, 1960.
    [Show full text]
  • Is Oral Morphine Still the First Choice Opioid for Moderate to Severe
    Review Palliative Medicine 25(5) 402–409 ! The Author(s) 2010 Is oral morphine still the first choice Reprints and permissions: sagepub.co.uk/journalsPermissions.nav opioid for moderate to severe cancer DOI: 10.1177/0269216310392102 pain? A systematic review within the pmj.sagepub.com European Palliative Care Research Collaborative guidelines project Augusto Caraceni Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Italy Alessandra Pigni Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Italy Cinzia Brunelli Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Italy Abstract The aim of this systematic review was to evaluate the evidence that oral morphine can be recommended as the first choice opioid in the treatment of moderate to severe cancer pain in updating the European Association for Palliative Care opioid recommendations. A systematic literature review was performed to update the 2007 Cochrane review ‘Oral morphine for cancer pain’. The literature search was conducted on MedLine, EMBASE and Cochrane Central Register of Controlled Trials databases. The search strategy, limited in time (from 1 July 2006 to 31 October 2009), was aimed to be as extensive as possible using both text words and MeSH/EMTREE terms; a hand search of the reference lists of identified papers was also performed. Randomized clinical trials, containing data on efficacy and/or side effects of morphine, were identified. Among the papers retrieved from the cited databases and the Cochrane review, 17 eligible studies, for a total of 2053 patients, and a meta-analysis were selected. These studies do not add significant information to the previous Cochrane review confirming the limitation of efficacy and tolerability data on opioid-naı¨ve and non-selected populations of cancer patients treated with morphine and suggesting that oral morphine, oxycodone and hydromorphone have similar efficacy and toxicity in this patient population.
    [Show full text]
  • Acetate, Administration Of, in Parenteral Nutrition Support, 102
    327 INDEX Acetate, administration of, in parenteral 50-52 nutrition support, 102 diagnostic tests for, 52-53 Acetominophen, 211, 213 prevention of, 55-58 Acidosis, correction of, with parenteral Aminoglycosides, nephro- and ototoxicity of, nutrition support, 102 11 Actinomycin D, 89 Amekacin, nephrotoxicity of, 11 Acylampicillins, toxic effects of, 10-11 Amphotericin B, chemical structure of, 16 Adenine diphosphate, effect of aspirin on, 212 combined with 5-flucytosine, for crypto- Adolescence, cancer statistics for, 291, 292 coccosis, 30 concept of body image during, 284-85 for aspergillosis, 27 coping strategies for disease during, 289-90 for candidiasis, 23, 24 current approach to cancer care during, for coccidioidomycosis, 31 281-82 for histoplasmosis, 32 emotional and physical development during, for mucormycosis, 28 282-86 for trichosporon infection, 31 general principles for management of cancer interaction of, with granulocyte trans- during, fusions, 73 activities, 298-99 pharmacokinetics of, 17 bereavement follow-up, 305 toxic effects of, 19 birth control, 300 Analgesic(s). See also names of specific drugs diagnosis, 293 classifications of, 206, 207 discussion of diagnosis, 293-98 controversial,231-33 financial expenses, 301-02 equianalgesic comparison of, 222-25 home care, 302-03 guidelines for selection and use of, 208 school program, 299-300 mechanisms of action by, 208-11 sibling care, 300-01 narcotic, supportive care, 298 cardiovascular effects of, 221 psychological impact of illness and hospital­ chemical classifications of, 216, 218 ization during, 287-89 effects of, on central nervous system, Adriamycin, emesis caused by, 89 219 hematopoietic effects of, 179 effects of, on endocrine system, 221 Aged.
    [Show full text]
  • Opioid Managementtm a Medical Journal for Proper and Adequate Use
    JOURNAL OF OPIOID MANAGEMENT OPIOID OF JOURNAL Journal of Opioid ManagementTM A medical journal for proper and adequate use Volume 3, Number 1 JANUARY/FEBRUARY 2007 ISSN 1551-7489 Official Journal of Opioid Management Society CONTENTS n GUEST EDITORIAL Patterns of illicit drug use and retention in a Can we continue to do business as usual? . 5 methadone program: A longitudinal study. 27 B. Eliot Cole, MD, MPA Ingrid Davstad, MA Marlene Stenbacka, PhD n OPIOID NEWS AND EVENTS Anders Leifman, MSE Calendar . 8 Olof Beck, PhD News briefs . 9 Seher Korkmaz, MD, PhD Anders Romelsjö, MD, PhD n PHARMACY PERSPECTIVE A randomized, open-label, multicenter trial Opioid administration for acute abdominal comparing once-a-day AVINZA® (morphine JANUARY/FEBRUARY 2007 pain in the pediatric emergency department . 11 sulfate extended-release capsules) versus twice- Adi Klein-Kremer, MD a-day OxyContin® (oxycodone hydrochloride Ran D. Goldman, MD controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: n LEGAL PERSPECTIVE Improved physical functioning in the ACTION trial . 35 Medicolegal rounds: Medicolegal issues and alleged breaches of standards of medical care Richard L. Rauck, MD in a patient motor vehicle accident allegedly Stephen A. Bookbinder, MD related to chronic opioid analgesic therapy . 16 Timothy R. Bunker, MD Christopher D. Alftine, MD David A. Fishbain, MD, FAPA Steven Gershon, MD John E. Lewis, PhD Egbert de Jong, MD Brandly Cole, PsyD Andres Negro-Vilar, MD, PhD Renné Steele Rosomoff, BSN, MBA Richard Ghalie, MD Hubert L. Rosomoff, MD, DMedSc, FAAPM n LITERATURE REVIEWS n ORIGINAL ARTICLES Buprenorphine: A unique opioid with broad Morphine prescription in end-of-life care and clinical applications .
    [Show full text]
  • Alcohol and Other Drugs: Realities for You and Your Family
    DOCUMENT RESUME ED 469 036 CE 082 510 AUTHOR Corrigan, Mary TITLE Alcohol and Other Drugs: Realities for You and Your Family. Health Promotion for Adult Literacy Students: An Empowering Approach. INSTITUTION Hudson River. Center for Program Development, Glenmont, NY. SPONS AGENCY New York State Univ. System, Albany.; New York State Education Dept., Albany. Office of Workforce Preparation and Continuing Education. PUB DATE 1994-00-00 NOTE 107p.; Funded under Section 326 of the Adult Education Act. Contributing authors were Colleen Bodane and Robin Granger Rischbieter. AVAILABLE FROM For full text: http://www.hudrivctr.org/dnload.htm#alcoh. PUB TYPE Guides Classroom Teacher (052) EDRS PRICE EDRS Price MF01/PC05 Plus Postage. DESCRIPTORS Adult Basic Education; Adult Learning; *Adult Literacy; Adult Students; Counseling Services; Definitions; Evaluation Criteria; Family Problems; Family Violence; Fused Curriculum; Glossaries; Guidelines; *Health Promotion; Helping Relationship; Instructional Materials; *Integrated Curriculum; Learning Modules; Lesson Plans; *Literacy Education; Medical Services; National Organizations; Nonprofit Organizations; Prevention; Rehabilitation Programs; Risk; Self Evaluation (Individuals); Self Help Programs; Social Support Groups; *Student Empowerment; *Substance Abuse IDENTIFIERS *New York; Relapse ABSTRACT This document is a learning module designed to provide adult literacy practitioners in New York and elsewhere with the materials needed to take an empowering approach to helping adult literacy learners deal with the realities of alcohol and other drug issues affecting them and their families. The module includes background material, information on resources, and sample lesson plans for use by instructors themselves or by guest presenters. The document begins with reading materials on the following topics: the history of substance abuse; substance use versus nonuse; elements of risk; associated risks; prevention; treatment options; self-help programs; recovery; and substance abuse in others around us.
    [Show full text]
  • Rand Study Answers Some Questions About the Effects of Ppis
    News Downloaded from https://academic.oup.com/ajhp/article/38/11/1635/5200642 by guest on 28 September 2021 Rand Study Answers Some Questions about the Effects of drug therapy are much affected hy receiving a PPI. Most PPis respondents elected to take the drug once they had pur­ chased it; only a few seem to have chrmged their decision as Patient package inserts (PPIs) fared well in an FDA-spon a result of the information they received. sored study of alternative designs by the Rand Corporation. The 5. The costs of returned prescriptions are likely to be quite low. Previous estimates of the annual cost of returned pre­ study showed that patients read and understand PPIs, do not scriptions that will result from FDA's proposed labeling report more side effects as a result of reading PPIs, and can ' program have been as high as $87.75 million—a figure based handle fairly lengthy and complex PPIs. on the assumption that for every 60 new prescriptions, PPIs will cause one additional prescription to he returned. These The Rand study was conducted from autumn 1979 through results indicate that this estimate is several orders of mag­ spring 1980 at 69 pharmacies in Los Angeles County, CA. Al­ nitude too high. During the course of the study, only three ternative PPIs were studied for three drugs: erythromycin, prescriptions were returned to pharmacies for cash refunds, conjugated estrogens, and flurazepam. Six variables of PPIs out of more than 2000 prescriptions dispensed with PPIs. Even if pharmacies were to pass on the full costsof returned were included: specificity of instructions, amount of explanation, pr^riptions to the consiuner, the resulting increases in drug writing style, risk emphasis, format, and reduced content prices would he extremely small.
    [Show full text]
  • Psychotropic Drugs G
    Postgrad Med J: first published as 10.1136/pgmj.60.710.881 on 1 December 1984. Downloaded from Postgraduate Medical Journal (December 1984) 60, 881-885 Psychotropic drugs G. W. HANKS B.Sc., M.B., M.R.C.P. The Royal Marsden Hospital, Fulham Road, London SW3 6JJ Introduction system-depressant effect ofthese drugs: by depressing the general level of arousal the central perception of The interaction between the cognitive component pain may be modified. (the perception ofnociceptive, or painful stimuli) and In this review the evidence for intrinsic analgesic the affective component of pain is reflected in the activity and overlap between the actions of anti-nociceptive the place of psychotropic drugs in the agents (analgesics) and mood-altering drugs (psycho- treatment of chronic pain are discussed in the light of tropics) when treating pain patients. Anxiety, depres- the published literature and recent clinical experi- sion, fear and sleeplessness may all respond to ence. psychotropic drugs, and this may result in a reduc- tion in pain or a greater ability to cope with it. This TABLE 1. The WHO classification of psychotropic drugs may enable a patient's pain to be controlled with a Neuroleptics by copyright. smaller dose of analgesic. In this sense psychotropic Anxiolytic sedatives drugs have an 'analgesic' effect but it is a misleading Antidepressants use of the word, and has been the source of much Psychostimulants misunderstanding. Psychodysleptics In the day-to-day management of pain problems the two groups of drugs do have well-defined indications. Acute pain is invariably associated with Neuroleptics nociception, and responds to analgesics or other Neuroleptics are antipsychotic agents of which the antinociceptive treatments.
    [Show full text]
  • Cancer Pain Relief Since 1945, Using Sociological, Historical and Ethical Perspectives
    Evaluation in cancer pain: from private to public trouble? Jane Seymour, University of Sheffield David Clark, Lancaster University Co-researchers: Michelle Winslow, Bill Noble, Fiona Graham, Silvia Paz, Henk ten Have, Marcia Meldrum Project aim and objectives Aim To analyse the global development of innovative technologies for cancer pain relief since 1945, using sociological, historical and ethical perspectives. Objectives To construct a narrative history of cancer pain relief since 1945, identifying key forms of technological innovation. To conduct two case studies of cancer pain innovation 1) the clinical domain 2) the public health domain identifying in each case ‘critical incidents’ of innovation and key drivers. Methods: see Final report to the ESRC, award no.: L218252055 Clark D et al www.regard.ac.uk Culture, technology and the cancer pain experience : the early days ‘I enquired why narcotics were not available for men and was told that men don’t need powerful drugs like that. It is hard to believe that such attitudes existed, but they did …it is worth recording that life was very bad sometimes for people with severe pain’[1] [1] Professor Sir Michael Bond, in: Reynolds LA and Tansey EM (eds) (2004) Wellcome Witnesses to Twentieth Century Medicine, Volume 21: Innovation in Pain Management. London: Wellcome Trust Centre for the History of Medicine at UCL, p21. Overview 1. The transformation of morphine from ‘last resort’ to ‘gold standard’ 2. A commercial space for innovation: new products and their evaluative criteria 3. New products and resource poor countries: the concept of ‘balance’ The transformation of morphine from ‘last resort’ to ‘gold standard’ Early changes • From liberal use in the early 20th century, to rapid regulation and moral panic about addiction: ‘…we are often loath to give liberal amounts of opiates because the drug addiction itself may become a hideous spectacle and actually result in great misery for the patient’[i], p8 [i] Cole W (1956) Foreword In: MJ Schiffin (ed) The Management of Pain in Cancer.
    [Show full text]
  • Correspondence
    1348 BRITISH MEDICAL JOURNAL 19 NOVEMBER 1977 CORRESPONDENCE Value of cocaine in opiate-containing Hexachlorophane-yes or no? Doctors and the global population crisis elixirs J M Gowdy, MD ...................... 1353 Sheila A Adam, MRCP, and Ann McPher- R G Twycross, DM .................... 1348 Indomethacin in pleurisy 4 son, MB .............................. 1356 The perilous skateboard K P Goldman, FRCP .................. /reatment of hepatic hydatid disease D H Wilson, FRCSED; C D Jefferiss, FRCS; 1353/ M Danis, MD, and others Quality v quantity in children .1356 Margaret I Little, MRCPSYCH ............ 1349 Relapse in leprosy Primary excision of brain abscess H P Dunn, FRCOG ...... .............. 1354 K Jesudasan .1356 J S Garfield, FRCS; A J Keogh, FRCS ...... 1349 Fatal chlormethiazole poisoning in Indomethacin, prostaglandins, and Treating dissenters chronic alcoholics schizophrenia S Bloch, MB, and P B Reddaway, MA .... 1349 Joan M Horder, MRCPATH .............. 1354 D F Horrobin, BM .1357 Science, race, and intelligence Outpatient chemotherapy for breast Alpha-fetoprotein in antenatal B R Silk, MRCP ...... ................ 1350 cancer diagnosis of neural tube defects Incidence and mortality of acute B V Palmer, FRCS ...................... 1354 R Carachi, FRCS ....... ............... 1357 pancreatitis Asymptomatic gonorrhoea in men M J McMahon, FRCS; C W Imrie, Blood for antenatal tests M J Balsdon, MRCOG, and H S K Singha, L G R Hull, MRCS .................... 1354 FRCSGLAS .............. .............. 1350 FRCS ................................ 1357 Role of the hospital in primary Association of autoimmune diseases SI units paediatric care with HLA-B8 J E Trapnell, FRCS .1357 G M Komrower, FRCP ...... .......... 1350 J von Knorring, MD ...... ............ 1354 Cancer of the lung and bladder Names of drugs Renal failure associated with ergot S Walter, MD, and others .1357 R Ham, MRCGP .....
    [Show full text]
  • The Hospice Concept in Health Care Kathleen Ann Allen
    The Hospice Concept in Health Care Kathleen Ann Allen The hospice movement has been receiving a great deal of attention lately. Care of the dying has become the byline for any professional as well as non-professional writers. You are sure to find at least one article in any current journal for health professionals devoted to the care of the terminally ill. Television has presented news miniseries and specials on the needs of the dying, and syndicated columnists, such as Sylvia Porter, have written on the subject. Why all this interest in the dying? 4hy all this interest by the health professionals who have been dealing with dying clients for centuries? One answer has been to attribute this recent attention to the fact that people are now living longer than even a half-century ago. However, the answer is quite likely much more complex than that. There is currently an internal evaluation process being carried out in most health related facilities. These evaluation procedures have evolved from government and con- sumer demands over recent years. It has become a recognized fact that within the medical and nursing professions not enough attention has been given to the care of the dying and/or the handling of the dying client. Attempts are made to correct this dilemma. Medical and nurai1:,; schools are now offering courses and recommending them to their students on such topics as "Perspectives on Death and Dying." They have not reached a required status in most college curricula; however, death and dying is at least accepted as a topic to be discussed in the professional preparation of the future health care practitioners in this country.
    [Show full text]
  • New Approaches to Treatment of Chronic Pain: a Review of Multidisciplinary Pain Clinics and Pain Centers
    New Approaches to Treatment of Chronic Pain: A Review of Multidisciplinary Pain Clinics and Pain Centers Editor: Lorenz K.Y. Ng, M.D. National Institute on Drug Abuse NIDA Research Monograph 36 May 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NlDA Reseach Monogaph series is prepared by the Division of Research of the National lnstitute on Drug Abuse. lts primary objective is to provide critical reviews of research problem ares and techniques, the content of state-of-the-art conferences, integrative research review and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric lnstitute University of California San Francisco, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education. DHHS Washington, D.C. Lee Robins, Ph.D. Washington University School of Medicine St Louis, Missouri NIDA Research Monograph series William Pollin, M.D. DIRECTOR, NIDA Marvin Snyder, Ph.D. DIRECTOR, DIVISION OF RESEARCH, NIDA Robert C. Petersen, Ph.D. EDITOR-IN-CHIEF Eleanor W. Waldrop MANAGING EDITOR Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857 New Approaches to Treatment of Chronic Pain: A Review of Multidisciplinary Pain Clinics and Pain Centers ACKNOWLEDGMENTS This monograph is based upon papers presented at a conference which took place on June 20-21, 1980, at the National Institutes of Health, Bethesda, Maryland.
    [Show full text]
  • Supportive Care Editorial
    Supportive Care Editorial Cancer Pain and Opioids—Past, Present, and Future Gregory B Crawford, MBBS, MPHC, MD, FRACGP, FAChPM Senior Consultant in Palliative Medicine, Director of Research & Education, Northern Adelaide Palliative Service, Adelaide, Australia; Associate Professor of Palliative Medicine, Discipline of Medicine, University of Adelaide, Australia Abstract The Cancer Council Australia and Cancer Institute New South Wales are two Australian organizations that are providing useful resources to support evidence-based prescribing of opioids in cancer pain. Morphine remains the preeminent medication for nociceptive cancer pain. Our understanding of the action of opioids, and how relatively recently these developments are, assists in putting pain and suffering in the context of “total pain.” Increasing understanding of the how pain is understood is leading to new insights with an increasing emphasis on the neuro- immuno-pharmacology of pain. Keywords Cancer pain, morphine, opioid conversion, neuro-immuno-pharmacology Disclosure: Gregory B Crawford, MBBS, MPHC, MD, FRACGP, FAChPM, has no conflicts of interests to declare. No funding was received in the publication of this article. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit. Received: February 23, 2015 Accepted: February 24, 2015 Citation: Oncology & Hematology Review, 2015;11(1):56–7 DOI: 10.17925/OHR.2015.11.01.56 Correspondence: Gregory B Crawford, MBBS, MPHC, MD, FRACGP, FAChPM, Associate Professor of Palliative Medicine, Discipline of Medicine, University of Adelaide, 5005 Australia. E: [email protected] Recent Australian initiatives have improved the use and safety of Morphine, named after Morpheus, the classical God of Dreams,5 has held opioid prescribing.
    [Show full text]